Aktis Oncology: Funding, Investors & Team (Oct 2026)
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.
Aktis Oncology has raised $84.0M across 1 funding round on record, the most recent a Series A of $84.0M announced in Aug 2022.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Aktis Oncology Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Aktis Oncology Funding Rounds
Aktis Oncology Founders and Leadership Team
No contact details are on record for this team yet.
Aktis Oncology Funding Compared to Other Biotechnology Startups
Aktis Oncology's latest round of $84.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Aktis Oncology in Biotechnology and Boston
Companies Similar to Aktis Oncology
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Aktis Oncology Funding FAQs
What does Aktis Oncology do?
Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.
How much funding has Aktis Oncology raised?
Aktis Oncology has raised $84.0M across 1 round on record. The most recent is a Series A of $84.0M announced in Aug 2022.
When did Aktis Oncology last raise funding?
Aktis Oncology's most recent funding round on record is a Series A of $84.0M, announced in Aug 2022.
Who founded Aktis Oncology?
FundedIQ lists Brian Goodman (Founder) at Aktis Oncology.
Where is Aktis Oncology headquartered?
Aktis Oncology is based in Boston, Massachusetts, United States.
How many employees does Aktis Oncology have?
Aktis Oncology is in the 1-10 employee band.
How does Aktis Oncology's funding compare to other Biotechnology startups?
Aktis Oncology's latest round of $84.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Aktis Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Aktis Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.